NRTX 1001
Alternative Names: GABA-secreting interneurons; NRTX-1001; NTX-001 - Neurona TherapeuticsLatest Information Update: 29 Jul 2024
At a glance
- Originator Neurona Therapeutics
- Class Pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Partial epilepsies
- Preclinical Alzheimer's disease
Most Recent Events
- 29 Jul 2024 Preclinical trials in Alzheimer's disease in USA (Intracerebral) (Neurona Therapeutics pipeline, July 2024)
- 18 Jun 2024 NRTX 1001 receives Regenerative Medicine Advanced Therapy (RMAT) status for Partial epilepsies in USA
- 14 Jun 2024 Neurona Therapeutics plans a phase I trial in Temporal lobe epilepsy (Treatment-resistant) (Intracerebral) (NCT06422923)